Clinical trial
Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic…
NCT00058396 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00058396 |
|---|---|
| Title | Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| Official title | Phase I Study Of IDEC-152 (Anti-CD23 Monoclonal Antibody) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma |
| Intervention type | Biological |
| Interventions | lumiliximab |
| Start date | Oct 1, 2002 |
| Primary completion | Oct 1, 2004 |
| First posted | Apr 9, 2003 |
| Last update posted | May 30, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: